Skip to main content

Table 2 Backward Cox’s proportional hazards regression analysis

From: Plasmacytoid variant of bladder cancer defines patients with poor prognosis if treated with cystectomy and adjuvant cisplatin-based chemotherapy

Variables in the equationb
  B SE Wald df Significance Exp(B) 95.0% Confidence interval for Exp(B)
lower upper
Step 1 age -.151 .232 .422 1 .516 .860 .546 1.356
gender -.046 .281 .027 1 .870 .955 .550 1.657
pT    .432 3 .933    
pT(1) .146 .795 .034 1 .854 1.157 .244 5.495
pT(2) .047 .464 .010 1 .919 1.048 .422 2.602
pT(3) .185 .307 .364 1 .546 1.203 .659 2.196
Grade .301 .351 .733 1 .392 1.351 .679 2.690
pN -.468 .239 3.842 1 .050 .626 .392 1.000
M    . 0a .    
Adjuvant Chemo    2.790 2 .248    
Adjuvant Chemo(1) -.359 .538 .446 1 .504 .698 .243 2.005
Adjuvant Chemo(2) .313 .233 1.806 1 .179 1.368 .866 2.160
Histo subtype    7.017 2 .030    
Histo subtype(1) 1.095 .588 3.463 1 .063 2.988 .943 9.466
Histo subtype (2) .261 .535 .237 1 .626 1.298 .455 3.703
Step 3 age -.148 .221 .446 1 .504 .863 .559 1.331
gender -.078 .275 .081 1 .776 .925 .539 1.585
Grade .270 .335 .650 1 .420 1.310 .679 2.528
pN -.436 .226 3.737 1 .053 .646 .415 1.006
Adjuvant Chemo    2.621 2 .270    
Adjuvant Chemo(1) -.360 .538 .448 1 .503 .697 .243 2.002
Adjuvant Chemo(2) .294 .229 1.642 1 .200 1.342 .856 2.103
Histo subtype    7.587 2 .023    
Histo subtype(1) 1.150 .581 3.920 1 .048 3.157 1.012 9.852
Histo subtype(2) .298 .523 .325 1 .569 1.348 .483 3.759
Step 4 age -.152 .221 .474 1 .491 .859 .558 1.324
Grade .270 .336 .649 1 .421 1.310 .679 2.529
pN -.437 .226 3.743 1 .053 .646 .415 1.006
Adjuvant Chemo    2.576 2 .276    
Adjuvant Chemo(1) -.375 .535 .490 1 .484 .687 .241 1.963
Adjuvant Chemo(2) .285 .227 1.576 1 .209 1.330 .852 2.075
Histo subtype    7.516 2 .023    
Histo subtype(1) 1.155 .580 3.959 1 .047 3.173 1.017 9.895
Histo subtype(2) .317 .519 .372 1 .542 1.373 .496 3.797
Step 5 Grade .292 .333 .766 1 .381 1.339 .697 2.574
pN -.420 .224 3.522 1 .061 .657 .423 1.019
Adjuvant Chemo    2.442 2 .295    
Adjuvant Chemo(1) -.358 .535 .449 1 .503 .699 .245 1.993
Adjuvant Chemo(2) .278 .226 1.506 1 .220 1.320 .847 2.056
Histo subtype    7.388 2 .025    
Histo subtype(1) 1.144 .580 3.890 1 .049 3.141 1.007 9.792
Histo subtype (2) .315 .519 .368 1 .544 1.370 .496 3.787
Step 6 pN -.434 .223 3.771 1 .052 .648 .418 1.004
Adjuvant Chemo    2.328 2 .312    
Adjuvant Chemo(1) -.399 .532 .561 1 .454 .671 .237 1.905
Adjuvant Chemo(2) .256 .224 1.298 1 .255 1.291 .832 2.004
Histo subtype    6.980 2 .030    
Histo subtype (1) 1.145 .580 3.896 1 .048 3.143 1.008 9.800
Histo subtype(2) .357 .516 .478 1 .489 1.429 .520 3.928
Step 7 pN -.404 .222 3.307 1 .069 .667 .432 1.032
Histo subtype    8.123 2 .017    
Histo subtype (1) 1.162 .580 4.015 1 .045 3.197 1.026 9.964
  Histo subtype (2) .302 .515 .344 1 .558 1.352 .493 3.709
  1. a. Degree of freedom is reduced because of constant or linear dependent covariates.
  2. b. Constant or linear dependent covariate M = 1; Significant values are marked in bold face.
  3. Exp(B) equals relative risk value (RR).
  4. Abbreviations and further information.
  5. Age: was grouped in group1 ≤ 60years and group 2 > 60 years.
  6. Gender: female (reference) and male groups.
  7. pT: tumor stage; pT(1)-tumor stage 1: pT(2) tumor stage 2; pT(3): tumor stage 3; (tumor stage 4 is reference).
  8. Grade: tumor grade: tumor grade 2 and tumor grade 3 (reference).
  9. pN: lymph node status, was grouped in group1=N0 and group2=N≥1 (N1, N2, N3, reference group).
  10. M: metastates status, group1without metastases (M0) and group 2 with metastases (M1), only one patient in group 2 therefore no calculations were performed.
  11. Adjuvant Chemo: Adjuvant Chemotherapy in 3 groups: Adjuvant Chemo(1) is treated with Gc = Gemcitabine, Cisplatin, Adjuvant Chemo(2) is treated with M-vec = Methotrexate, Vinblastine, Epirubicin, Cisplatin and the group treated with CM = Cisplatin, Methotrexate is the reference group.
  12. Histo subtype: Histology subtypes in 3 groups: Histo subtype(1) is the plasmacytoid urothelial carcinoma patients’ group, Histo subtype(2) is the conventional urothelial carcinoma patients’ group and the group with the micropapillary urothelial carcinoma patients is the reference group.